InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.120 -0.04 (-25%)+
Announcement
Release
8 Jul 2026 10:09AM
Price at Release
$0.160
Full Release
download
Summary
Proteomics International Laboratories Ltd, a company specializing in precision diagnostics, has secured a US patent for its PromarkerEndo diagnostic test for endometriosis. The patent, titled 'Endometriosis Biomarkers,' provides intellectual property protection until March 2041 and covers the methods of diagnosing endometriosis using specific protein biomarkers in blood samples. This patent is a significant milestone in the company’s global commercialization strategy, enhancing its position for future partnerships and licensing opportunities, particularly in the United States, the world's largest healthcare market.
Key Points
  • Proteomics International Laboratories Ltd (ASX: PIQ) secured a US patent for their PromarkerEndo diagnostic test.
  • The patent, titled 'Endometriosis Biomarkers' (US Patent No. 12674806), protects a diagnostic test for endometriosis.
  • The patent covers methods of diagnosing endometriosis using specific protein biomarkers in blood samples.
  • Patent protection is expected to extend until March 2041.
  • This development marks a significant milestone in the global commercialization strategy for PromarkerEndo.
  • The US patent strengthens Proteomics International’s intellectual property portfolio, crucial for future partnerships and licensing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.